Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma

Michael J. Robertson, Brad S. Kahl, Julie M. Vose, Sven De Vos, Mary Laughlin, Patrick J. Flynn, Kendrith Rowland, Jose C. Cruz, Stuart L. Goldberg, Luna Musib, Christelle Darstein, Nathan Enas, Jeffery L. Kutok, Jon C. Aster, Donna Neuberg, Kerry J. Savage, Ann LaCasce, Donald Thornton, Christopher A. Slapak, Margaret A. Shipp

Research output: Contribution to journalArticlepeer-review

233 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science